Advertisement

Hellenic Journal of Surgery

, Volume 91, Issue 1, pp 22–32 | Cite as

Neoadjuvant Treatment of Locally Advanced Soft Tissue Sarcoma of the Extremities to Avoid Amputation. Isolated Limb Perfusion is a Valid Option

  • Eelco de BreeEmail author
  • D. Michelakis
  • C. Ioannou
  • J. Romanos
  • K. Lasithiotakis
  • O. Zoras
Review Article
  • 1 Downloads

Abstract

The goals of treatment for soft tissue sarcoma (STS) of the extremities are local tumor control, preservation of limb function and reduction of the risk of distant metastasis. The standard treatment for STS of the limbs is wide local excision with histologically negative margins and, in the majority of cases, adjuvant radiotherapy. In the case of locally advanced tumors, this might not be feasible, especially when the tumor is located at the periphery of the limb, or tumor infiltration, encasement or fixation of motor nerves, major vessels or bones has occurred, in which case, amputation may be necessary. The aim of neoadjuvant treatment is to minimize the need for amputation or surgery that leads to major functional impairment with an acceptable level of toxicity and without a negative impact on survival.

This is a comprehensive review of the various neoadjuvant treatment strategies applied in an attempt to salvage the limb and to preserve its function in patients with locally advanced STS. Systemic chemotherapy with regional hyperthermia and isolated limb infusion (ILI) are promising. Novel treatment option such as, isolated limb perfusion (ILP) with tumor necrosis factor-α (TNF-α) and melphalan appears to be the most effective neoadjuvant treatment modality for these cases. ILP provides the highest likelihood of local tumor eradication with preservation of the limb and its function for patients with limb-threatening locally advanced STS. Approximately one quarter of the patients experience complete pathological response and half of the patients a partial response, together resulting in limb salvage in three quarters of the patients. Because of the high pathological response rates, the high limb salvage rate, the improved surgical margins after ILP with TNF-α and melphalan, and its low toxicity, the indications for performing this treatment should be evaluated for primary and recurrent tumors when infiltration, encasement and/or fixation of motor nerves, major vessels, or bones are present.

When ILP is indicated, the limited availability of the technique, which is provided at present by only one center in Greece, should not be a reason to withhold from a patient the opportunity of salvage of the limb and its function.

Key words

Soft tissue sarcoma extremity neoadjuvant treatment limb salvage isolated limb perfusion 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7–30.CrossRefGoogle Scholar
  2. 2.
    Cronin KA, Lake AJ, Scott S, et al. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer 2018;124:2785–800.CrossRefGoogle Scholar
  3. 3.
    ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25 Suppl 3:iii102–12.CrossRefGoogle Scholar
  4. 4.
    Dangoor A, Seddon B, Gerrand C, et al. UK guidelines for the management of soft tissue sarcomas. Clin Sarcoma Res 2016;6:20.CrossRefGoogle Scholar
  5. 5.
    NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Soft Tissue Sarcoma Version 1.2018. Available from: https://doi.org/www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf. Last visited at December 30, 2018.
  6. 6.
    Stevenson MG, Musters AH, Geertzen JHB, et al. Amputations for extremity soft tissue sarcoma in an era of limb salvage treatment: Local control and survival. J Surg Oncol 2018;117:434–42.CrossRefGoogle Scholar
  7. 7.
    Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: Prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982;196:305–15.CrossRefGoogle Scholar
  8. 8.
    Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998;16:197–203.CrossRefGoogle Scholar
  9. 9.
    Pisters PW, Harrison LB, Leung DH, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996;14:859–68.CrossRefGoogle Scholar
  10. 10.
    Davis AM, O’Sullivan B, Bell RS, et al. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol 2002;20:4472–7.CrossRefGoogle Scholar
  11. 11.
    O’Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: A randomised trial. Lancet 2002;359:2235–41.CrossRefGoogle Scholar
  12. 12.
    Al-Absi E, Farrokhyar F, Sharma R, et al. A systematic review and meta-analysis of oncologic outcomes of pre- versus postoperative radiation in localized resectable soft-tissue sarcoma. Ann Surg Oncol 2010;17:1367–74.CrossRefGoogle Scholar
  13. 13.
    Chung PW, Deheshi BM, Ferguson PC, et al. Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma: A comparison with other soft tissue sarcomas. Cancer 2009;115:3254–61.CrossRefGoogle Scholar
  14. 14.
    Koseła-Paterczyk H, Szumera-Ciećkiewicz A, Szacht M, et al. Efficacy of neoadjuvant hypofractionated radiotherapy in patients with locally advanced myxoid liposarcoma. Eur J Surg Oncol 2016;42:891–8.CrossRefGoogle Scholar
  15. 15.
    Callegaro D, Miceli R, Bonvalot S, et al. Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: Retrospective analysis across major histological subtypes and major reference centres. Eur J Cancer 2018;105:19–27.CrossRefGoogle Scholar
  16. 16.
    Krikelis D, Judson I. Role of chemotherapy in the management of soft tissue sarcomas. Expert Rev Anticancer Ther 2010;10:249–60.CrossRefGoogle Scholar
  17. 17.
    Gronchi A, Casali PG. Adjuvant therapy for high-risk soft tissue sarcoma in the adult. Curr Treat Options Oncol 2013;14:415–24.CrossRefGoogle Scholar
  18. 18.
    Constantinidou A, Pollack S, Loggers E, et al. The evolution of systemic therapy in sarcoma. Expert Rev Anticancer Ther 2013;13:211–23.CrossRefGoogle Scholar
  19. 19.
    Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008;113:573–81.CrossRefGoogle Scholar
  20. 20.
    Woll PJ, Reichardt P, Le Cesne A, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): A multicentre randomised controlled trial. Lancet Oncol 2012;13:1045–54.CrossRefGoogle Scholar
  21. 21.
    Gortzak E, Azzarelli A, Buesa J, et al. A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma. Eur J Cancer 2001;37:1096–103.CrossRefGoogle Scholar
  22. 22.
    Gronchi A, Frustaci S, Mercuri M, et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: A randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol 2012;30:850–6.CrossRefGoogle Scholar
  23. 23.
    Gronchi A, Stacchiotti S, Verderio P, et al. Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): Long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. Ann Oncol 2016;27:2283–8.CrossRefGoogle Scholar
  24. 24.
    Kraybill WG, Harris J, Spiro IJ, et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol 2006;24:619–25.CrossRefGoogle Scholar
  25. 25.
    Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): An international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol 2017;18:812–22.CrossRefGoogle Scholar
  26. 26.
    de Bree E, Romanos J, Tsiftsis DD. Hyperthermia in anticancer treatment. Eur J Surg Oncol 2002;28:95.CrossRefGoogle Scholar
  27. 27.
    Storm FK. Clinical hyperthermia and chemotherapy. Radiol Clin N Am 1989;27:621–7.Google Scholar
  28. 28.
    Hippocratis. Aphorisms. In: Omni Opera Hippocratis, F Asulanus (editor). Venice; Aldine Press; 1526, pp. 172.Google Scholar
  29. 29.
    Lepock JR. How do cells respond to their thermal environment? Int J Hyperthermia 2005;21:681–7.CrossRefGoogle Scholar
  30. 30.
    Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am 2003;12:689–701.CrossRefGoogle Scholar
  31. 31.
    de Bree E, Tsiftsis DD. Principles of perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis. Recent Results Cancer Res 2007;169:39–51.Google Scholar
  32. 32.
    Issels RD. Hyperthermia adds to chemotherapy. Eur J Cancer 2008;44:2546–54.CrossRefGoogle Scholar
  33. 33.
    Urano M, Kuroda M, Nishimura Y. For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthemia 1999;15:79–107.CrossRefGoogle Scholar
  34. 34.
    Urano M, Ling CC. Thermal enhancement of melphalan and oxaliplatin cytotoxicity in vitro. Int J Hyperthermia 2002;18:307–15.CrossRefGoogle Scholar
  35. 35.
    Issels RD, Lindner LH, Verweij J, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: A randomised phase 3 multicentre study. Lancet Oncol 2010;11:561–70.CrossRefGoogle Scholar
  36. 36.
    Issels RD, Lindner LH, Verweij J, et al. Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes among patients with localized high-risk soft tissue sarcoma: The EORTC 62961-ESHO 95 randomized clinical trial. JAMA Oncol 2018;4:483–92.CrossRefGoogle Scholar
  37. 37.
    Creech O Jr, Krementz ET, Ryan RF, et al. Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958;148:616–32.CrossRefGoogle Scholar
  38. 38.
    Merimsky O, Meller I, Issakov J, et al. Adriamycin-ifosfamide induction chemotherapy for extremity soft tissue sarcoma: Comparison of two non-randomized protocols. Oncol Rep 1999;6:913–20.Google Scholar
  39. 39.
    Nijhuis PH, Pras E, Sleijfer DT, et al. Long-term results of preoperative intra-arterial doxorubicin combined with neoadjuvant radiotherapy, followed by extensive surgical resection for locally advanced soft tissue sarcomas of the extremities. Radiother Oncol 1999;51:15–9.CrossRefGoogle Scholar
  40. 40.
    Wanebo HJ, Temple WJ, Popp MB, et al. Preoperative regional therapy for extremity sarcoma. A tricenter update. Cancer 1995;75:2299–306.CrossRefGoogle Scholar
  41. 41.
    Azzarelli A, Quagliuolo V, Fissi S, et al. Intra-arterial induction chemotherapy for soft tissue sarcomas. Ann Oncol 1992;3 Suppl 2:S67–70.CrossRefGoogle Scholar
  42. 42.
    Kónya A, Vigváry Z. Neoadjuvant intraarterial chemotherapy of soft tissue sarcomas. Ann Oncol 1992;3 Suppl 2:S127–9.CrossRefGoogle Scholar
  43. 43.
    Kroon BBR, Kroon HM, Noorda EM, et al. Isolated limb perfusion for melanoma. In: Aigner K, Stephens F, editors. Induction chemotherapy. Cham: Springer; 2016. pp. 355–73.Google Scholar
  44. 44.
    Stamatiou D, Ioannou CV, Kontopodis N, et al. Hyperthermic isolated limb perfusion. The switch from Steinmann pins to Omni-tract assisted isolation. J Surg Res 2017;213:147–57.CrossRefGoogle Scholar
  45. 45.
    Hoekstra HJ, van Ginkel RJ. Hyperthermic isolated limb perfusion in the management of extremity sarcoma. Curr Opin Oncol 2003;15:300–3.CrossRefGoogle Scholar
  46. 46.
    Jakob J, Hohenberger P. Role of isolated limb perfusion with recombinant human tumor necrosis factor a and melphalan in locally advanced extremity soft tissue sarcoma. Cancer 2016;122:2624–32.CrossRefGoogle Scholar
  47. 47.
    Rastrelli M, Campana LG, Valpione S, et al. Hyperthermic isolated limb perfusion in locally advanced limb soft tissue sarcoma: A 24-year single-centre experience. Int J Hyperthermia 2016;32:165–72.CrossRefGoogle Scholar
  48. 48.
    de Bree E, Michelakis D, Ioannou C, et al. Isolated limb perfusion for soft tissue sarcoma of the extremities. Hell Surg Oncol 2017;8:6–16.Google Scholar
  49. 49.
    Schwarzbach M, Lehnert T, Willeke F, et al. Results of isolated hyperthermic extremity perfusion in soft tissue sarcomas within the scope of a multimodality treatment concept [in German]. Chirurg 1996;67:1237–43.CrossRefGoogle Scholar
  50. 50.
    Lienard D, Ewalenko P, Delmotte JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52–60.CrossRefGoogle Scholar
  51. 51.
    Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001;104:487–501.CrossRefGoogle Scholar
  52. 52.
    Lenk H, Tanneberger S, Muller U, et al. Phase II clinical trial of high-dose recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 1989;24:391–2.CrossRefGoogle Scholar
  53. 53.
    Lejeune FJ, Ruegg C. Recombinant human tumor necrosis factor: An efficient agent for cancer treatment. Bull Cancer 2006;93:E90–100.Google Scholar
  54. 54.
    Ruegg C, Yilmaz A, Bieler G, et al. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998;4:408–14.CrossRefGoogle Scholar
  55. 55.
    Folli S, Pelegrin A, Chalandon Y, et al. Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer 1993;53:829–36.CrossRefGoogle Scholar
  56. 56.
    Jahr J, Grande PO. In vivo effects of tumor necrosis factor-alpha on capillary permeability and vascular tone in a skeletal muscle. Acta Anaesthesiol Scand 1996;40:256–61.CrossRefGoogle Scholar
  57. 57.
    de Wilt JH, ten Hagen TL, de Boeck G, et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000;82:1000–3.CrossRefGoogle Scholar
  58. 58.
    Daryanani D, Komdeur R, Ter Veen J, et al. Continuous leakage measurement during hyperthermic isolated limb perfusion. Ann Surg Oncol 2001;8:566–72.CrossRefGoogle Scholar
  59. 59.
    Casara D, Rubello D, Pilati P, et al. Optimized procedure of real-time systemic leakage monitoring during isolated limb perfusion using a hand held gamma probe and 99mTc-HSA. Nucl Med Commun 2004;25:61–6.CrossRefGoogle Scholar
  60. 60.
    Grünhagen DJ, de Wilt JH, van Geel AN, et al. Isolated limb perfusion with TNF-alpha and melphalan in locally advanced soft tissue sarcomas of the extremities. Recent Results Cancer Res 2009;179:257–70.CrossRefGoogle Scholar
  61. 61.
    Möller MG, Lewis JM, Dessureault S, et al. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. Int J Hyperthermia 2008;24:275–89.CrossRefGoogle Scholar
  62. 62.
    Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996;224:756–64.CrossRefGoogle Scholar
  63. 63.
    Eggermont AM, Schraffordt Koops H, Liénard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial. J Clin Oncol 1996;14:2653–65.CrossRefGoogle Scholar
  64. 64.
    Wieberdink J, Benckhuysen C, Braat RP, et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905–10.CrossRefGoogle Scholar
  65. 65.
    Grünhagen DJ, de Wilt JH, Graveland WJ, et al. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer 2006;106:1776–84.CrossRefGoogle Scholar
  66. 66.
    Neuwirth MG, Song Y, Sinnamon AJ, et al. Isolated limb perfusion and infusion for extremity soft tissue sarcoma: A contemporary systematic review and meta-analysis. Ann Surg Oncol 2017;24:3803–10.CrossRefGoogle Scholar
  67. 67.
    Pace M, Galli A, Bellacci A. Local and systemic toxicity in ‘borderline true’ hyperthermic isolated perfusion for lower limb melanoma. Melanoma Res 1995;5:371–6.CrossRefGoogle Scholar
  68. 68.
    Vrouenraets BC, Klaase JM, Nieweg OE, et al. Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol 1998;14:224–31.CrossRefGoogle Scholar
  69. 69.
    Bonvalot S, Laplanche A, Lejeune F, et al. Limb salvage with isolated perfusion for soft tissue sarcoma: Could less TNF-alpha be better? Ann Oncol 2005;16:1061–8.CrossRefGoogle Scholar
  70. 70.
    Hoven-Gondrie ML, Bastiaannet E, van Ginkel RJ, et al. TNF dose reduction and shortening of duration of isolated limb perfusion for locally advanced soft tissue sarcoma of the extremities is safe and effective in terms of long-term patient outcome. J Surg Oncol 2011;103:648–55.CrossRefGoogle Scholar
  71. 71.
    Jakob J, Tunn PU, Hayes AJ, et al. Oncological outcome of primary non-metastatic soft tissue sarcoma treated by neoadjuvant isolated limb perfusion and tumor resection. J Surg Oncol 2014;109:786–90.CrossRefGoogle Scholar
  72. 72.
    Jakob J, Smith HG, Wilkinson MJ, et al. Regional chemotherapy by isolated limb perfusion prior to surgery compared with surgery and post-operative radiotherapy for primary, locally advanced extremity sarcoma: a comparison of matched cohorts. Clin Sarcoma Res 2018;8:12.CrossRefGoogle Scholar
  73. 73.
    Hohenberger P, Wysocki WM. Neoadjuvant treatment of locally advanced soft tissue sarcoma of the limbs: Which treatment to choose? Oncologist 2008;13:175–86.CrossRefGoogle Scholar
  74. 74.
    Grabellus F, Podleska LE, Sheu SY, et al. Neoadjuvant treatment improves capsular integrity and the width of the fibrous capsule of high-grade soft-tissue sarcomas. Eur J Surg Oncol 2013;39:61–7.CrossRefGoogle Scholar
  75. 75.
    Cherix S, Speiser M, Matter M, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients. J Surg Oncol 2008;98:148–55.CrossRefGoogle Scholar
  76. 76.
    Pennacchioli E, Deraco M, Mariani L, et al. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. Ann Surg Oncol 2007;14:553–9.CrossRefGoogle Scholar
  77. 77.
    Grabellus F, Kraft C, Sheu-Grabellus SY, et al. Tumor vascularization and histopathologic regression of soft tissue sarcomas treated with isolated limb perfusion with TNF-alpha and melphalan. J Surg Oncol 2011;103:371–9.CrossRefGoogle Scholar
  78. 78.
    Smith HG, Wilkinson MJ, Smith MJF, et al. The effect of age on outcomes after isolated limb perfusion for advanced extremity malignancies. Eur J Cancer 2018;100:46–54.CrossRefGoogle Scholar
  79. 79.
    Rastrelli M, Mocellin S, Stramare R, et al. Isolated limb perfusion for the management limb threatening soft tissue sarcomas: The role of histological type on clinical outcomes. Eur J Surg Oncol 2017;43:401–6.CrossRefGoogle Scholar
  80. 80.
    Huis In’ tVeld EA, Grünhagen DJ, Verhoef C, et al. Isolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study. Eur J Cancer 2017;85:114–21.CrossRefGoogle Scholar
  81. 81.
    Deroose JP, Eggermont AM, van Geel AN, et al. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. J Clin Oncol 2011;29:4036–44.CrossRefGoogle Scholar
  82. 82.
    Podleska LE, Kaya N, Farzaliyev F, et al. Lower limb function and quality of life after ILP for soft-tissue sarcoma. World J Surg Oncol 2017;15:84.CrossRefGoogle Scholar
  83. 83.
    Grünhagen DJ, de Wilt JH, Graveland WJ, et al. The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer 2006;106:156–62.CrossRefGoogle Scholar
  84. 84.
    Mullinax JE, Kroon HM, Thompson JF, et al. Isolated limb infusion as a limb salvage strategy for locally advanced extremity sarcoma. J Am Coll Surg 2017;224:635–42.CrossRefGoogle Scholar
  85. 85.
    Vohra NA, Turaga KK, Gonzalez RJ, et al. The use of isolated limb infusion in limb threatening extremity sarcomas. Int J Hyperthermia 2013;29:1–7.CrossRefGoogle Scholar
  86. 86.
    Turaga KK, Beasley GM, Kane JM 3rd, et al. Limb preservation with isolated limb infusion for locally advanced non-melanoma cutaneous and soft-tissue malignant neoplasms. Arch Surg 2011;146:870–5.CrossRefGoogle Scholar
  87. 87.
    Moncrieff MD, Kroon HM, Kam PC, et al. Isolated limb infusion for advanced soft tissue sarcoma of the extremity. Ann Surg Oncol 2008;15:2749–56.CrossRefGoogle Scholar
  88. 88.
    Hegazy MA, Kotb SZ, Sakr H, et al. Preoperative isolated limb infusion of Doxorubicin and external irradiation for limb-threatening soft tissue sarcomas. Ann Surg Oncol 2007;14:568–76.CrossRefGoogle Scholar
  89. 89.
    Salah S, Lewin J, Amir E, et al. Tumor necrosis and clinical outcomes following neoadjuvant therapy in soft tissue sarcoma: A systematic review and meta-analysis. Cancer Treat Rev 2018;69:1–10.CrossRefGoogle Scholar

Copyright information

© Hellenic Surgical Society 2019

Authors and Affiliations

  • Eelco de Bree
    • 1
    • 4
    Email author
  • D. Michelakis
    • 1
  • C. Ioannou
    • 2
  • J. Romanos
    • 1
  • K. Lasithiotakis
    • 3
  • O. Zoras
    • 1
  1. 1.Department of Surgical OncologyMedical School of Crete University HospitalHeraklionGreece
  2. 2.Department of Vascular SurgeryMedical School of Crete University HospitalHeraklionGreece
  3. 3.Department of General SurgeryMedical School of Crete University HospitalHeraklionGreece
  4. 4.Department of Surgical OncologyUniversity HospitalHeraklionGreece

Personalised recommendations